The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors (NCT07651020) | Clinical Trial Compass
CompletedNot Applicable
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
China1 participantsStarted 2025-03-01
Plain-language summary
Here's a polished version of the text:
"This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian cancer, head and neck tumors, colorectal cancer, melanoma, etc., as well as healthy volunteers. Using a targeted LRRC15-specific SPECT imaging agent, SPECT/CT imaging is performed to achieve the following objectives:
For malignant tumor patients:
To support disease diagnosis and staging. Diagnostic performance will be evaluated against the gold standard of pathological diagnosis, clarifying the presence or absence of lesions and determining their location and nature.
To enable accurate staging and assess tumor burden by comparison with \[18F\]FDG PET/CT, thereby aiding in the determination of treatment plans.
For healthy volunteers:
To conduct pharmacokinetic analysis, elucidating the distribution, metabolism, and safety profile of the agent in the body."
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF);
. Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study;
. Adult patients or healthy volunteers, aged 18 years or older, male or female;
. Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition;
. Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is already completed and was testing a SPECT imaging agent that targets something called LRRC15 — could you explain what LRRC15 is and whether my specific cancer type, like pancreatic or breast cancer, is one where this marker tends to show up?
2Since this was an imaging study rather than a treatment trial, what were they actually hoping to learn about how tumors absorb or 'light up' with this tracer, and could that kind of scan eventually change how my cancer is diagnosed or staged?
3The trial covered a wide range of cancers including glioblastoma, sarcoma, and melanoma — does the fact that my cancer type was included tell us anything useful about whether LRRC15 might be a relevant target in my case specifically?
4Now that this trial is completed, is there any published data or follow-up research I should know about, and could the findings influence whether I might be eligible for a future treatment trial that actually targets LRRC15?
5Since this was a diagnostic imaging study with no listed phase, what does that mean for how much is actually known about the safety and reliability of this tracer, and are there any risks worth discussing before I consider any related imaging or treatment options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Visual and standardized uptake values assessment of lesions and biodistribution
Timeframe: 1 year
Trial details
NCT IDNCT07651020
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
. Must meet any other protocol-specified inclusion criteria.
Exclusion criteria
. Inability to tolerate or complete SPECT/CT examinations (including, but not limited to, the inability to lie supine, claustrophobia, radiophobia, etc.);
. Presence of other comorbidities, such as acute systemic illnesses and electrolyte imbalances;
. Known allergy or hypersensitivity to the LRRC15 radiotracer or its synthetic excipients; fasting blood glucose level exceeding 11.0 mmol/L prior to \[¹⁸F\]FDG injection;
. Patients deemed by the investigator to have poor expected compliance;
. Pregnant or lactating (nursing) women;
. Presence of any other conditions or factors that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.